|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Transgene to Present Positive Results from Phase 1b Trial of TG1050 in Patients with Chronic Hepatitis B at Upcoming AASLD Liver Meeting 2018
Prof Fabien Zoulim will report that the Phase 1b trial reached its safety primary endpoint and that the therapeutic vaccine TG1050 breaks immune tolerance in patients with chronic hepatis B virus (HBV) infection
Transgene will also present new and promising preclinical data set on combination studies of TG1050 with antivirals and immunomodulators
October 10, 2018 12:00 PM Eastern Daylight Time
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies, announces that the detailed results of the Phase 1b clinical trial using TG1050 confirm that the safety primary endpoint was reached and that TG1050 breaks immune tolerance through improvement of immune response directed against HBV antigens in patients with chronic HBV receiving standard antiviral therapies. The complete Phase 1b data will be presented by Prof Fabien Zoulim, MD, PhD, on November 9, 2018, at the annual meeting of the AASLD (American Association for the Study of Liver Diseases) in San Francisco (USA).
Transgene will also present new and promising preclinical data that showed an improved antiviral activity of TG1050 (including on the decrease of circulating HBV surface antigen - HBsAg) when administered in combination with direct acting antivirals or immunomodulators in HBV-persistent mice.
Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study
Presenter: Prof Fabien Zoulim, principal investigator of the trial and head of the gastro-enterology service of the Croix-Rousse Hospital (Lyon, France)
Abstract number: 426
Session date, time and location: Session I, November 9, 2018, 12 pm-1.30 pm (PT), Hall C
Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice
Presenter: Roland Kratzer, Transgene
Abstract number: 438
Session date, time and location: Session I, November 9, 2018, 12 pm-1.30 pm (PT), Hall C
Both abstracts published in Hepatology can be downloaded from the AASLD website. |
-
总评分: 现金 + 1
查看全部评分
|
发表于 2018-10-11 15:33
